Comparative Effectiveness of Efavirenz-based Antiretroviral Regimens in Resource-limited Settings

Overview

Journal J Comp Eff Res

Specialty Health Services

Date 2012 Jun 19

PMID 22707879

Citations 4

Authors

Jose R Castillo-Mancilla

Thomas B Campbell

Affiliations

Soon will be listed here.

Abstract

Efavirenz (EFV) is a non-nucleoside widely used as first-line therapy for HIV-1 infection. Most of the research available on EFV comes from trials performed in industrialized countries and only a few studies have evaluated EFV in resource-limited settings (RLSs). In this article, we present a systematic review of the available randomized-controlled trials performed in RLSs that have compared EFV with other antiretrovirals, such as nevirapine and protease inhibitors. The data derived from these studies show that both EFV and nevirapine are adequate first-line therapy options for HIV-1 infection in RLSs, even in patients with concomitant tuberculosis. However, EFV may show a slight benefit in terms of toxicity and adverse events. By contrast, the data comparing EFV versus protease inhibitors is contradictory and further studies may be required to elucidate these discrepancies.

Citing Articles

Proposal of pharmacophore model for HIV reverse transcriptase inhibitors: Combined mutational effect analysis, molecular dynamics, molecular docking and pharmacophore modeling study.

Annan A, Raiss N, Lemrabet S, Elomari N, Elmir E, Filali-Maltouf A Int J Immunopathol Pharmacol. 2024; 38:3946320241231465.

PMID: 38296818 PMC: 10832406. DOI: 10.1177/03946320241231465.

Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele.

Bordin Andriguetti N, Van Schalkwyk H, Barratt D, Tucci J, Pumuye P, Somogyi A Clin Transl Sci. 2021; 14(6):2521-2531.

PMID: 34415664 PMC: 8604234. DOI: 10.1111/cts.13120.

Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children.

Kekitiinwa A, Szubert A, Spyer M, Katuramu R, Musiime V, Mhute T Pediatr Infect Dis J. 2017; 36(6):588-594.

PMID: 28505015 PMC: 5533213. DOI: 10.1097/INF.0000000000001505.

Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis.

Pillay P, Ford N, Shubber Z, Ferrand R PLoS One. 2013; 8(7):e68995.

PMID: 23894391 PMC: 3718822. DOI: 10.1371/journal.pone.0068995.

References

Cooper D, Heera J, Goodrich J, Tawadrous M, Saag M, DeJesus E . Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010; 201(6):803-13. DOI: 10.1086/650697. View

Robbins G, de Gruttola V, Shafer R, Smeaton L, Snyder S, Pettinelli C . Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003; 349(24):2293-303. PMC: 4767257. DOI: 10.1056/NEJMoa030264. View

Lennox J, DeJesus E, Lazzarin A, Pollard R, Madruga J, Berger D . Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009; 374(9692):796-806. DOI: 10.1016/S0140-6736(09)60918-1. View

El-Ibiary S, Cocohoba J . Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. Eur J Contracept Reprod Health Care. 2008; 13(2):123-32. DOI: 10.1080/13625180701829952. View

Thompson M, Aberg J, Cahn P, Montaner J, Rizzardini G, Telenti A . Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010; 304(3):321-33. DOI: 10.1001/jama.2010.1004. View

Mbanya D, Assah F, Ndembi N, Kaptue L . Monitoring antiretroviral therapy in HIV/AIDS patients in resource-limited settings: CD4 counts or total lymphocyte counts?. Int J Infect Dis. 2006; 11(2):157-60. DOI: 10.1016/j.ijid.2006.02.008. View

van den Berg-Wolf M, Hullsiek K, Peng G, Kozal M, Novak R, Chen L . Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. HIV Clin Trials. 2008; 9(5):324-36. DOI: 10.1310/hct0905-324. View

Bangsberg D, Ragland K, Monk A, Deeks S . A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS. 2010; 24(18):2835-40. PMC: 3540404. DOI: 10.1097/QAD.0b013e328340a209. View

Bussmann H, Wester C, Wester C, Lekoko B, Okezie O, Thomas A . Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana. J Acquir Immune Defic Syndr. 2007; 45(3):269-73. DOI: 10.1097/QAI.0b013e318050d683. View

10.

van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B . Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004; 363(9417):1253-63. DOI: 10.1016/S0140-6736(04)15997-7. View

11.

Gulick R, Ribaudo H, Shikuma C, Lustgarten S, Squires K, Meyer 3rd W . Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004; 350(18):1850-61. DOI: 10.1056/NEJMoa031772. View

12.

Hodder S, Mounzer K, DeJesus E, Ebrahimi R, Grimm K, Esker S . Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care STDS. 2010; 24(2):87-96. DOI: 10.1089/apc.2009.0259. View

13.

Hoffmann C, Charalambous S, Sim J, Ledwaba J, Schwikkard G, Chaisson R . Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis. 2009; 49(12):1928-35. PMC: 2789416. DOI: 10.1086/648444. View

14.

Gallant J, Rodriguez A, Weinberg W, Young B, Berger D, Lim M . Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis. 2005; 192(11):1921-30. DOI: 10.1086/498069. View

15.

Squires K, Lazzarin A, Gatell J, Powderly W, Pokrovskiy V, Delfraissy J . Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004; 36(5):1011-9. DOI: 10.1097/00126334-200408150-00003. View

16.

Staszewski S, Morales-Ramirez J, Tashima K, Rachlis A, Skiest D, Stanford J . Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999; 341(25):1865-73. DOI: 10.1056/NEJM199912163412501. View

17.

Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Kumar S, Iliayas S . Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin Infect Dis. 2011; 53(7):716-24. DOI: 10.1093/cid/cir447. View

18.

Patel D, Thorne C, Fiore S, Newell M . Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women?. J Acquir Immune Defic Syndr. 2005; 40(1):116-8. DOI: 10.1097/01.qai.0000156854.99769.a5. View

19.

Sierra-Madero J, Villasis-Keever A, Mendez P, Mosqueda-Gomez J, Torres-Escobar I, Gutierrez-Escolano F . Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico. J Acquir Immune Defic Syndr. 2010; 53(5):582-8. DOI: 10.1097/QAI.0b013e3181cae4a1. View

20.

Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W . A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis. 2009; 48(12):1752-9. DOI: 10.1086/599114. View